Diabetes

As of now, data suggest minimal risk of drug interactions between oral contraceptives and injectable semaglutide.

The weight loss drug continues to show promise in treating a variety of other conditions.

The results validate the protective benefits of the sodium–glucose cotransporter-2 inhibitors on renal function for those with type 2 diabetes.

Each stage of the CGM battery lifecycle contains the potential for detrimental environmental impact.

Empathy is being left outside the exam room door.

Three of the largest pharmacy benefit managers ––Express Scripts, Optum, and Caremark––are listed in the suit.

Eversense 365 (Senseonics) is the first long-lasting continuous glucose monitoring (CGM) system, which includes a 365-day sensor and only 1 insertion on Day 1 of every year.

Data show the value of the pharmacist is clear for patients with type 2 diabetes, as their role can have a significant impact on reductions in hemoglobin A1c.

Pharmacists should be aware of these digital therapeutics, which are often used as an adjunct to medication, to better understand the treatment outcomes.

Previously, the device was indicated for the management of type 1 diabetes in patients aged 2 years and older.

Clinical improvements for patients with diabetes seen in a collaboration between the University of North Carolina and Blue Cross and Blue Shield of North Carolina.

For adults receiving the 15 mg dose, tirzepatide sustained weight loss with an average reduction of 22.9% in body weight compared with 2.1% for the placebo.

Glucagon-like peptide-1 receptor agonists and sodium-glucose contransporter-2 inhibitors have been added as first-line therapy recommendation for type 2 diabetes, the first since metformin

Many patients are unaware of wound complication, so it is valuable for pharmacists to communicate prevention methods with all patients with diabetes.

The use of CGMs in pregnancy provides clinicians with essential data in real-time, rather than a snapshot given by traditional finger stick testing.

The ADA Clinical Practice Recommendations added sleep assessment for precision medicine in type 2 diabetes, supporting the wealth of information surrounding the association.

The system is an outpatient procedure that resurfaces the mucosal lining, making it easier for the body to maintain healthy metabolism and blood glucose levels.

The presence of glutamic acid decarboxylase antibodies in intravenous immunoglobulin can lead to a misdiagnosis of type 1 diabetes mellitus if a false-positive result is garnered.

A 5:2 intermittent fasting plan combined with meal replacement had better positive outcomes compared with metformin and empagliflozin.

Use of semaglutide injections may be linked to an increased risk of blindness in patients with diabetes.

The FDA has issued a statement on suicidal thoughts or actions and has launched evaluations for that signal as well as alopecia and aspiration.

When used correctly, weight-loss medications, such as glucagon-like peptide-1 (GLP-1) medications, can be a tool to help reduce costs and provide clinical results.

Many patients who took technosphere insulin saw improvements in hemoglobin A1c, but other patients saw worsening with the drug.

Additionally, birth weight was higher in babies born to mothers who were prescribed glucagon-like peptide-1 (GLP-1) medications either 90 days prior to pregnancy or during the first trimester.

Approximately 81% of individual said Tandem Mobi reduced the burden of managing diabetes and 87% said it helped manage diabetes effectively.

This marks the first launch of a generic glucagon-like peptide 1 receptor agonist.

American Diabetes Association Scientific Sessions speaker Ivan de Araujo discusses how regulation of blood glucose levels and the influence of food preferences can be significant for diabetes care.

Benefits of semaglutide on cardiovascular outcomes, such as death, non-fatal myocardial infarction, and non-fatal stoke, were also presented at the session at American Diabetes Association 84th Scientific Sessions.

Teplizumab (Tzield; Sanofi) has the potential to delay type 1 diabetes and the onset of stage 3 diabetes, but must be started in stage 1 of the disease.